Please note that this meeting will take place as an in-person event in Boston and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the REGISTRATION page for details. 

CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise.  Program is subject to change.

*-Denotes Short Talk from Proffered Abstract
[R]-Remote Presentation

Tuesday, September 13

Welcome and Keynote Lectures

wednesday, September 14

Plenary Session 1: Disparities and Health Equity
Plenary Session 2: Bench to Bedside: The Science that Underpins Clinical Trials
Plenary Session 3: Tumor Plasticity and Drug Resistance

thursday, September 15

Plenary Session 4: Challenges in Treating Locally Advanced Pancreatic Cancer
Plenary Session 5: Prevention and Interception
Plenary Session 6: Tumor Microenvironment

friday, September 16

Plenary Session 7: Immunobiology and Immunotherapy
Plenary Session 8: Metabolism and Microbiome
Debate: Targeting the Tumor vs. Stroma

Tuesday, September 13

Welcome and Keynote Lectures
6-7:25 p.m.

Welcome from Cochairs
Andrew M. Lowy, UC San Diego, La Jolla, California

Welcome from Lead Supporter
Andrew Rakeman, Lustgarten Foundation, Woodbury, New York          

Rising Star Keynote
Truncated O-glycosylation in pancreatic cancer
Avery D. Posey Jr., University of Pennsylvania, Philadelphia, Pennsylvania

Opening Keynote
Contextual determinants of pancreatic tumorigenesis
Dafna Bar-Sagi, NYU Langone Medical Center, New York, New York

Poster session A/Opening Reception
7:30-9 p.m.

Wednesday, September 14

Breakfast Round Tables
7-8 A.M.

How to Get a Paper Published
Robert Vonderheide, Penn Medicine Abramson Cancer Center, Philadelphia, Pennsylvania

How to Write a Grant
Marina Pasca di Magliano, University of Michigan Medical School, Ann Arbor, Michigan
Howard C. Crawford, Henry Ford Pancreatic Cancer Center, Detroit, Michigan

Starting Your Lab
Katelyn T. Byrne, Oregon Health & Science University, Portland, Oregon
Yuliya Pylayeva-Gupta, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Getting Tenure
Edna Cukierman, Fox Chase Cancer Center, Philadelphia, Pennsylvania

Balancing Clinical and Research Life
Andrew M. Lowy, UC San Diego, La Jolla, California
Diane Simeone, New York University, New York, New York

Plenary Session 1: Disparities and Health Equity
Session Chair:  Maria Elena Martinez, UCSD Moores Cancer Center, La Jolla, California
8-10 A.M.

Advocating for health equity in pancreatic cancer
Karen Winkfield, Meharry-Vanderbilt Alliance, Nashville, Tennessee

Socioeconomic analysis and disparities in germline genetic testing for pancreatic cancer*
Xianghui Zou, North Shore University Hospital & Long Island Jewish Medical Center, New Hyde Park, New York

Transcriptomic influences of racial disparities in Black patients with pancreatic neuroendocrine tumors*
Brendon Herring, University of Alabama at Birmingham, Birmingham, Alabama  

Race plays a role on the rate of transdifferentiation in human pancreatic acinar ductal metaplasia and its’ drug response*
Corey Perkins, University of Florida, Gainesville, Florida

System-level approaches to cancer care equity [R]
Cleo A. Samuel-Ryals, Flatiron Health, New York, New York

Break
10-10:30 A.M.

Plenary Session 2: Bench to Bedside: The Science that Underpins Clinical Trials
Session Chair: Diane Simeone, New York University, New York, New york
10:30 a.m.–12:30 p.m.

Generating T cell responses against pancreatic cancer
Katelyn T. Byrne, Oregon Health & Science University, Portland, Oregon

Were the mice right? Applying immunobiological insights from the lab to the treatment of patients with pancreatic cancer
Robert Vonderheide, Penn Medicine Abramson Cancer Center, Philadelphia, Pennsylvania

Characterizing the effects of neoadjuvant therapy in PDAC*
Amaya Pankaj, Mass General Cancer Center, Harvard Medical School, Boston, Massachusetts

Primary results of PanCAN-SR1, a phase 1b study evaluating Gemcitabine, nab-Paclitaxel, Canakinumab, and Spartalizumab to target IL-1β and PD-1 in metastatic pancreatic cancer with correlative tissue and blood biomarker analysis*
Paul Oberstein, NYU Langone Health, New York, New York

Initial results of a cohort of advanced pancreatic cancer patients in a phase 1b study of NGM120, a first-in-class anti-GDNF Family Receptor Alpha Like (GFRAL) antibody*
Andrew Hendifar, Cedars-Sinai Medical Center, Los Angeles, California

Lunch on Own
12:30-2 P.M.

Plenary Session 3: Tumor Plasticity and Drug Resistance
Session Chair: Scott W. Lowe, Memorial Sloan Kettering Cancer Center, New York, New York
2–4 p.m.

How important is cell state in cancer?
Alex K. Shalek, Massachusetts Institute of Technology, Cambridge, Massachusetts

Three-dimensional genomic analysis of human pancreatic intraepithelial neoplasia (PanIN) reveals striking multifocality and genetic heterogeneity*
Alicia Braxton, Johns Hopkins Medical Institute, Baltimore, Maryland

Overcoming PDAC T cell therapy barriers with CD47-targeted costimulatory fusion proteins*
Shannon Oda, Seattle Children’s Research Institute, University of Washington, Seattle, Washington

An epigenetic memory of inflammation controls context-dependent lineage plasticity in the pancreas*
David Falvo, Weill Cornell Medicine, New York, New York

Single-cell sequencing elucidates the effects of chemotherapy on cancer cell heterogeneity and the tumor microenvironment of human pancreatic adenocarcinoma*
Daniel Weissinger, Perlmutter Cancer Center, New York University Langone Health, New York, New York

The origins and function of copy number alterations in pancreas cancer
Scott W. Lowe, Memorial Sloan Kettering Cancer Center, New York, New York

Poster Session b/Reception
4-6 P.M.

Thursday, September 15

Breakfast Roundtables
7-8 A.M.

How to Write a Grant
Marina Pasca di Magliano, University of Michigan Medical School, Ann Arbor, Michigan
Jen Jen Yeh, University of North Carolina, Chapel Hill, North Carolina

Collaborating with Industry (begins at 7:30 a.m.)
Eileen O’Reilly, Memorial Sloan Kettering Cancer Center, New York, New York

Starting Your Lab
Howard C. Crawford, Henry Ford Pancreatic Cancer Center, Detroit, Michigan

Balancing Clinical and Research Life
Andrew M. Lowy, UC San Diego, La Jolla, California
Kimberly Perez, Dana-Farber Cancer Institute, Boston, Massachusetts

Plenary Session 4: Challenges in Treating Locally Advanced Pancreatic Cancer
Session Chair: Andrew M. Lowy, UC San Diego, La Jolla, California
8-10 A.M.

Total Neoadjuvant Therapy for Pancreatic Cancer: The role of radiation therapy
Theodore S. Hong, Massachusetts General Hospital, Boston, Massachusetts

Proteomic profiling reveals subtype specific kinase expression in pancreatic cancer*
Yi Xu, University of North Carolina, Chapel Hill, North Carolina

Perioperative liver biopsy captures features of the liver pre-metastatic niche and predicts metastatic outcome after pancreatic cancer resection*
Linda Bojmar, Cornell University, New York, New York

Meeting the challenge of pancreatic cancer
Philip A. Philip, Henry Ford Cancer Center, Detroit, Michigan

Precision oncology approaches in pancreatic cancer
Jen Jen Yeh, University of North Carolina, Chapel Hill, North Carolina

Break
10-10:30 A.M.

Plenary Session 5: Prevention and Interception
Session chair: Sapna Syngal, Dana-Farber Cancer Institute, Boston, Massachusetts
10:30 A.M.-12:30 P.M.

Intraductal papillary mucinous neoplasms of the pancreas, an opportunity to prevent pancreatic cancer
Peter J. Allen, Duke University School of Medicine, Durham, North Carolina

High sensitive mutation detection in liquid biopsy with duodenal fluid captures genetic mutations associated with pancreatic carcinogenesis*
Yusuk Ono, Institute of Biomedical Research, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan

Evaluating circulating tumor DNA by targeted next generation sequencing as a biomarker in the treatment of localized pancreatic cancer*
Dhavan Shah, Northwestern University, Chicago, Illinois

Excess dietary oleic acid primes the pancreas for cancer*
Christian Ruiz, Yale University, New Haven, Connecticut

Intercepting pancreatic cancer development with mutant KRAS-targeted immunotherapy
Neeha Zaidi, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Lunch on Own
12:30-2 P.M.

Plenary Session 6: Tumor Microenvironment
Session Chair: Edna Cukierman, Fox Chase Cancer Center, Philadelphia, Pennsylvania
2-4 P.M.

Collagen cleavage controls PDAC metabolism and malignancy via a DDR1-NRF2 cascade and mitochondrial biogenesis
Michael Karin, UC San Diego, La Jolla, California

Aging modulates the tumor microenvironment of pancreatic cancer*
Joaquín Araos Henríquez, Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom

Stromal Netrin G1 ligand (NGL-1): a new modulator of tumorigenesis and immunosuppression in pancreatic cancer*
Debora Barbosa Vendramini Costa, Fox Chase Cancer Center, Philadelphia, Pennsylvania

Hypoxia synergizes with IL1 to promote an inflammatory fibroblast state in the pancreatic tumor microenvironment*
Simon Schwoerer, Memorial Sloan Kettering Cancer Center, New York, New York

Breaking down the PDAC tumor microenvironment
Rama Khokha, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada

Poster Session c/Reception
4-6 P.M.

Friday, September 16

Breakfast
7-8 A.M.

Plenary Session 7: Immunobiology and Immunotherapy
Session Chair: Marina Pasca di Magliano, University of Michigan Medical School, Ann Arbor, Michigan
8-10 A.M.

Determinants of B cell fate and function in cancer
Yuliya Pylayeva-Gupta, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Mutant KRAS-specific T cell receptors directed against prevalent G12D and G12V variants exhibit potent cytotoxic activity and CD8 co-receptor independence*
Adham Bear, University of Pennsylvania, Philadelphia, Pennsylvania

Cholinergic modulation of T lymphocytes in pancreatic adenocarcinoma*
Ruth White, Columbia University Medical Center, New York, New York

CCR1 expression defines pancreatic tumor associated macrophages and drives their immunosuppressive properties*
Yaqing Zhang, University of Michigan, Ann Arbor, Michigan

IL-17/IL-17RA signaling in the pancreatic epithelium upregulates CXCL5 and B7-H4 to promote tumorigenesis*
Le Li, UT MD Anderson Cancer Center, Houston, Texas

Break
10-10:30 A.M.

Plenary Session 8: Metabolism and Microbiome
Session Chair: Florencia McAllister, UT MD Anderson Cancer Center, Houston, Texas
10:30 A.M.-12:15 P.M.

The role of vitamin D receptor agonists in the treatment of pancreatic adenocarcinoma
Kimberly Perez, Dana-Farber Cancer Institute, Boston, Massachusetts

Targeting gemcitabine resistance in pancreatic cancer*
Alica Beutel, University of California, Irvine, Irvine, California

Investigating lipid homeostasis in pancreatic ductal adenocarcinoma under tumor-like stress*
Xu Han, University of Pennsylvania, Philadelphia, Pennsylvania

ATP production in pancreas cancer and tumor infiltrating lymphocytes
Joshua D. Rabinowitz, Princeton University, Princeton, New Jersey

Debate: Targeting the Tumor vs. Stroma
Moderator: Eileen O’Reilly, Memorial Sloan Kettering Cancer Center, New York, New York
12:15-1 P.M.

Targeting Stroma Argument: Sunil R. Hingorani, Fred & Pamela Buffett Cancer Center, Omaha, Nebraska

Targeting Tumor Argument: Howard C. Crawford, Henry Ford Pancreatic Cancer Center, Detroit, Michigan

Closing Remarks
1 P.M.

Marina Pasca di Magliano, University of Michigan Medical School, Ann Arbor, Michigan